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Background. Rats fed a high fat diet and given a low dose of
streptozotocin (STZ) (35 mg/kg) develop type 2 diabetes with
insulin resistance, hyperinsulinemia, moderate hyperglycemia,
hyperlipidemia, and salt-sensitive hypertension. We postulated
that rats with noninsulinopenic (type 2) diabetes develop le-
sions of diabetic nephropathy significantly more prominent than
those seen in classic insulinopenic (type 1) diabetic rats.
Methods. Rats were fed regular chow or high fat diet (60%
calories from fat and 70% animal fat). After 5 weeks, rats
fed regular chow received vehicle (controls) or 55 mg/kg STZ
(type 1 diabetes mellitus). Rats fed high fat diet received vehicle
(high fat) or low dose STZ, 35 mg/kg (type 2 diabetes mellitus).
Rats were sacrificed 14 weeks after STZ/vehicle injection.
Results. Blood glucose, systolic blood pressure, and uri-
nary protein excretion were significantly higher in both dia-
betes groups than in controls. Serum insulin levels (ng/mL)
were higher in type 2 diabetes than in type 1 diabetes groups
(0.49 ± 0.12 vs. 0.07 ± 0.07) (P = 0.01). Percentage of sclerosed
glomeruli was significantly higher in type 2 diabetes group than
in control and type 1 diabetes groups. Fibronectin expression
was significantly increased in high fat, type 1 and type 2 diabetes
groups compared to controls. The expression of type IV colla-
gen, connective tissue growth factor (CTGF), and transforming
growth factor-b (TGF-b) was significantly increased in high fat
and type 2 diabetes groups compared to controls.
Conclusion. Rats fed a high fat diet and given a low dose
of STZ developed diabetes (with normal/high insulin levels),
hypertension, and proteinuria. Kidney lesions in this type 2
model appear to be more pronounced than in type 1 diabetic
rats despite lower blood glucose levels and proteinuria. We
present a nongenetic rat model of type 2 diabetes mellitus and
nephropathy.
Diabetic nephropathy is the major cause of end-stage
renal disease (ESRD) in the United States. The majority
of these patients are affected by type 2 diabetes. Ani-
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mal models of type 2 diabetes allow performing detailed
and mechanistic testing, including direct examination of
tissue to assess pathology that is difficult or impossible
to perform in clinical studies. At the present time there
are no nongenetic animal models of type 2 diabetes and
nephropathy. Rat strains with defects causing type 2 di-
abetes are expensive, difficult to obtain, and in most of
these the genetic defect has not been well characterized
yet [1, 2]. For example, metabolic abnormalities in the
Zucker diabetic fatty rat (ZDF/Drt-fa) closely mimics
those found in patients with type 2 diabetes. These rats
develop obesity, hyperlipidemia, insulin resistance, hy-
perinsulinemia (and eventual hypoinsulinemia), hyper-
glycemia, spontaneous proteinuria, and renal lesions of
focal segmental glomerulosclerosis (FSGS) leading to
renal failure. Unfortunately, the presence of significant
nondiabetic renal lesions like hydronephrosis, renal ab-
scesses, pyelonephritis and granulomas limits the util-
ity of this model to study diabetic nephropathy [2, 3].
The widely accepted rat model of type 1 diabetes (in-
sulinopenic model) induced with high dose STZ has a
number of limitations when used to study diabetes. First,
animals are insulinopenic and require insulin replace-
ment. Because there is no agreement between investi-
gators on the regimen of insulin used (if used at all) and
the level of glycemic control achieved, there is a lot of
heterogeneity in the results reported using this model.
Second, animals are hypercatabolic if not treated with
insulin (different from the obesity seen in type 2 dia-
betes). Third, animals require administration of single
high dose of streptozotocin (STZ) (55 to 65 mg/kg) which
is associated with known nephrotoxic effects [4–6]. Fi-
nally, although these rats develop thickening of glomeru-
lar basement membrane (GBM), modest expansion of
mesangial matrix in the long term and variable tubuloin-
terstitial histopathology depending on rat species used,
they do not develop the typical diffuse and/or nodular
glomerulosclerosis seen in human diabetic nephropathy
[7, 8]. The epidemic of type 2 diabetes warrants an animal
model that more closely mimics the human pathophysiol-
ogy and kidney disease. A nongenetic model of type 2 dia-
betes has been described that involves feeding rats a high
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fat diet and administering a low dose of STZ [9]. Rats de-
velop diabetes with the following characteristics: (1) they
are insulin resistant; (2) they have measurable serum in-
sulin concentrations typically at or above normal levels;
(3) they have moderately elevated blood glucose levels
(about 300 mg/dL) without insulin treatment; (4) they
have increased levels of cholesterol, triglycerides, free
fatty acids, and lipoproteins; and (5) they are salt-sensitive
and hypertension-prone [10, 11]. These metabolic abnor-
malities are very similar to those seen in human type 2 di-
abetes which is associated with obesity, insulin resistance,
hyperlipidemia, and in a majority of cases salt-sensitive
hypertension [12]. Although this type 2 model of diabetes
was originally described in the mouse in 1998 [13], it is still
unknown whether the kidney pathology observed in this
type 2 model of diabetes will compare to that observed
in the established type 1 model.
HYPOTHESIS
Rats with diabetes induced by a combination of high
fat diet and low dose STZ will develop kidney lesions
significantly more severe than those seen in rats with the
classical high dose STZ-induced diabetes.
METHODS
Experimental design
All protocols were conducted in accordance with the
Institutional Animal Care and Use Committee of our
institution. Thirty-one age- and weight-matched male
Sprague-Dawley rats weighing 175 to 200 g (Harlan,
Indianapolis, IN, USA) were used for the studies. Rats
were housed in individual cages in a temperature con-
trolled room with a 14/10-hour light-dark cycle (starting
at 07:00 A.M.) and allowed to acclimate to the environ-
ment for 1 week before dietary intervention was initiated.
Diet and induction of diabetes
Rats were randomly assigned to either regular rat chow
(N = 16) or high fat diet (N = 15) (60% calories from fat
and 70% animal fat) (TD97201; Harlan Teklad, Madison,
WI, USA). All rats were given food and water ad libitum.
After 5 weeks on their respective diets, rats fed regular
chow were divided into three groups: controls (N = 5),
low dose (35 mg/kg) (N = 5), or high dose STZ (55 mg/kg)
(N = 6) (type 1 diabetes mellitus). A low dose of STZ,
regular rat chow, control group was included to compare
to the percentage of animals that develop diabetes with
the low dose of STZ given to the high fat diet–fed animals.
Rats fed high fat diet received either vehicle (N = 5) (high
fat) or low dose STZ (N = 10) (type 2 diabetes mellitus).
STZ was dissolved in citrate buffer (0.01 mol/L, pH 4.5)
and given by a single tail vein injection. For STZ injection,
animals were anesthetized using isofluorane inhalation
anesthesia. Control animals received intravenous citrate
buffer alone.
Noninvasive blood pressure measurement
Blood pressure and heart rate were measured us-
ing the noninvasive tail cuff plethysmography method
(IITC Inc., Life Science Instruments, Woodland Hills,
CA, USA). Blood pressure was measured under resting,
conscious condition in a climate-controlled room (23◦C).
Rats were trained to sit in Plexiglass restrainers placed
over a warming pad (29◦C) for 30 minutes each day for
5 consecutive days before blood pressure was measured.
During this acclimation period, the cuff was inflated and
deflated several times to condition the animals to the pro-
cedure. Five consecutive systolic blood pressure and si-
multaneous heart rate measurements were recorded and
the three readings in the median range used for analysis.
Determination of urine protein and creatinine
concentrations
Rats were placed in metabolic cages and urine col-
lected for 24 hours every 4 weeks for determination of
protein and creatinine excretion. Total protein excretion
was determined using the colorimetric assay Biuret pro-
tein assay (KNaC4H4O.4H2O and CuSO4.5H2O) [14,
15]. Urine creatinine was determined using an Olympus
auto analyzer (AU640) (Olympus Corp., Melville, NY,
USA) utilizing a kinetic modification of the Jaffe´ reac-
tion. Protein to creatinine ratio was then calculated. Uri-
nary albumin excretion was determined by western blot
analysis of the urine with affinity purified rabbit anti rat
albumin antibody (Immunology Consultants Laboratory,
Newberg, OR, USA).
Collection and storage of blood samples
Prior to STZ injection, blood was obtained from the tail
vein in tubes with 10 lL of 0.5 mol/L ethylenediaminete-
traacetic acid (EDTA). Samples were centrifuged at
10,000 rpm for 10 minutes and the supernatant plasma
separated, aliquoted, and immediately stored at −80◦C.
At the time of sacrifice, blood was also collected from the
aorta and plasma separated and stored as above.
Determination of blood glucose and hemoglobin
A1c (HbA1c)
Random, nonfasting, morning blood glucose concen-
tration was determined at 1- to 2-week intervals in
all groups by glucometer (Bayer Elite XL) (Bayer,
Pittsburgh, PA, USA) on blood samples obtained from
tail veins. HbA1c was determined on blood samples ob-
tained at the end of the 14-week study period using a
DCA 2000 analyzer (Bayer).
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Determination of serum insulin, creatinine,
and lipid profile
Serum insulin, creatinine, and lipid levels were deter-
mined from the blood samples obtained at the end of the
14-week study period. Serum insulin levels were deter-
mined using a sensitive rat antibody radioimmunoassay
(Linco Diagnostics, St. Charles, MO, USA). Serum crea-
tinine and serum lipid profile were determined using an
Olympus auto analyzer (AU640) (Olympus Corp.).
Routine histology
Rats were sacrificed 14 weeks after induction of dia-
betes to determine the morphologic changes in the kid-
ney. At sacrifice, kidneys were excised, cortical tissue
sliced, and portions fixed in neutral buffered formalin for
routine paraffin embedment and subsequent tissue stain-
ing by hematoxylin and eosin and Jones periodic acid-
Schiff (PAS) for bright-field microscopic evaluation. The
remaining cortex was sliced and frozen by immersion in
liquid nitrogen for subsequent detection of fibronectin
by Western blot analysis and immunoperoxidase histo-
chemistry as described below. The number of sclerotic
glomeruli were determined in Jones PAS-stained sections
by counting obsolescent glomeruli by a semiquantitative
scoring technique and reported as a percent of approxi-
mately 100 glomeruli examined in each slide.
Immunohistochemistry for cellular fibronectin
Localization of cellular fibronectin was assessed by im-
munoperoxidase histochemistry using the avidin-biotin-
complex (Vector Laboratories, Burlingame, CA, USA)
technique for immunoperoxidase as previously de-
scribed.[16] Acetone fixed frozen sections (6 lm) were
incubated with nonimmune donkey IgG to block non-
specific binding, then sections were incubated with 0.6%
hydrogen peroxide in methanol, to block nonspecific per-
oxidase activity and 0.01% avidin and 0.001% biotin to
block endogenous biotin activity. A mouse monoclonal
antibody specific for the alternatively spliced extra do-
main (ED-A) of cellular fibronectin (IST-9) (Serotec,
Harlan Bioproducts for Science, Indianapolis, IN, USA)
was used as the primary followed by biotin-labeled
donkey antimouse IgG (Chemicon International, Inc.,
Temecula, CA, USA). Signal was detected using the ABC
method with diaminobenzidine (DAB) substrate and de-
veloped according to the manufacturer’s instructions. All
incubations of primary and secondary antibodies were for
30 minutes with three washes with phosphate-buffered
saline (PBS) containing 0.1% bovine serum albumin
(BSA), 5 minutes each between steps. Controls consisted
of non-immune mouse IgG or PBS/BSA in place of pri-
mary antibody followed by detection procedures as out-
lined above.
The extent of DAB reaction product was measured us-
ing the segmentation tool of Image-Pro Plus 4.5 (Media
Cybernetics, Silverspring, MD, USA). Digital images
were taken of 40 randomly selected glomeruli in tissue
slides derived from each experiment. All images were
taken using a 20× objective and computer assisted image
analysis was used to measure area of DAB staining in each
glomerulus. The color of staining product was extracted
from the image by selecting a lower and upper range of
gray scale within the limits of background and the highest
intensity of staining. The circumference of the glomerulus
was outlined utilizing the polygonal tracing tool of Image-
Pro Plus; then the image data were masked and pseudo-
colored for measurement of total staining area relative
to the area of interest, set to encompass the glomeru-
lar capillary tuft. All images were calibrated to a stage
micrometer.
Determination of glomerular size by image analysis
The image analysis method used was similar to that
used for determination of area of glomerular fibronectin
staining. Digital images were taken of randomly se-
lected glomeruli in hematoxylin and eosin–stained sec-
tions. The circumference of each glomerulus was outlined
as above using the polygonal tracing tool of Image-Pro
Plus. Glomerular area was computed utilizing the spatial
measurement tool calibrated to a stage micrometer.
Western blot analysis
Kidney tissue was homogenized in RIPA buffer
[20 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl,
5 mmol/L EDTA, 1 mmol/L Na3VO4, 1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 20 lg/mL aprotinin,
20 lg/mL leupeptin, and 1% NP-40) for 30 minutes.
Whole kidney lysates were centrifuged at 10,000g for
30 minutes at 4◦C. Protein concentration was determined
in the cleared supernatant using the Bio-Rad method
(Bio-Rad, Hercules, CA, USA). For immunoblotting,
equal amounts of protein per lane were loaded and
electrophoresed under reducing conditions on polyacry-
lamide gels, and then transferred to nitrocellulose mem-
branes. The membranes were rinsed twice with TBST
buffer (150 mmol/L NaCl, 10 mmol/L Tris-HCl, and 0.1%
Tween 20) followed by incubation for 1 hour at room tem-
perature with TBST buffer with 2% nonfat milk powder.
This was followed by overnight incubation at 4◦C with
antibodies to fibronectin, type IV collagen, or transform-
ing growth factor-b (TGF-b). Horseradish peroxidase–
conjugated anti-IgG was used as a secondary antibody.
Membranes were then washed, and the reactive bands
were detected by chemiluminescence using the enhanced
chemiluminescence (ECL) system (Amersham, Bucking-
hamshire, UK). Primary antibodies used were (1) mouse
monoclonal antibody to a region in the ED-A domain
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Fig. 1. Blood glucose levels (mg/dL) obtained by tail vein puncture
during the study period at 2-week intervals. Rats with diabetes had
elevated blood glucose levels throughout the study compared to control
and high fat diet groups. High fat diet alone did not cause hyperglycemia.
DM is diabetes mellitus and STZ is streptozotocin. Data are mean ±
SE. ∗P < 0.05 vs. control; †P < 0.05 vs. high fat diet; ‡P < 0.05 vs. type 1
diabetes.
of human cellular fibronectin which crossreacts with hu-
man, mouse, rat, dog, and monkey (Abcam, Cambridge,
MA, USA), 1:5000 dilution; (2) polyclonal antibody to a
chains of type IV collagen which reacts with human, mon-
key, and rat (Chemicon International), 1:1000 dilution;
(3) rabbit polyclonal antibody to TGF-b detects TGF-b1,
TGF-b2, and TGF-b3 of mouse, rat, and human origin,
1:1000 dilution (Santa Cruz Biotechnology, Santa Cruz,
CA, USA); and (4) rabbit polyclonal antibody to recom-
binant fragment of mouse connective tissue growth fac-
tor (CTGF), 1:1000 dilution (Abcam), crossreacts with
human, mouse, and rat.
Statistical analysis
Significance of differences was determined by mul-
tiple sample comparison methods analysis of variance
(ANOVA) using Statview software (SAS Institute Inc.,
Cary, NC, USA). Differences were considered significant
if P < 0.05. Data are presented as mean ± SE.
RESULTS
Changes in blood glucose and HbA1c concentrations
Blood glucose levels are shown in Figure 1. All the ani-
mals in the type 1 diabetes mellitus group (high dose STZ)
became diabetic after injection of STZ (sustained blood
glucose levels >250 mg/dL). Low dose STZ (35 mg/kg)
induced diabetes mellitus in 70% (seven out of ten) of
the rats fed high fat diet but in only 40% (two out of
five) of those fed regular rat chow. Rats that did not de-
velop hyperglycemia in the type 2 diabetes mellitus group
were excluded from the study. Data from animals in the
low dose STZ regular rat chow group are not reported.
HbA1c concentrations in the four study groups are shown
in Table 1. Neither the controls on regular chow nor the
rats on high fat diet alone developed hyperglycemia by
the end of the study period.
Changes in body weight
Body weights during the observation period are shown
in Figure 2. At the time of STZ/vehicle injection animals
fed a high fat diet for the prior 5 weeks were heavier than
the animals in the regular rat chow group. Animals in
the high fat diet group continued to gain weight and were
heavier than control animals throughout the study period
(high fat diet 494 ± 14 g and control 458 ± 13 g). Rats
with type 2 diabetes mellitus had regained their pre-STZ
injection weight at the time of sacrifice (378 ± 26 g). In
contrast animals in the type 1 diabetes mellitus group con-
tinued to lose weight during the follow-up period (324 ±
20 g).
Changes in serum insulin levels
Serum insulin levels at the end of the study period are
shown in Table 1. Before injection of STZ, rats fed a
high fat diet had significantly higher insulin levels than
rats fed regular rat chow (0.67 ± 0.05 ng/mL and 0.39 ±
0.086 ng/mL, respectively). At the end of the study period,
insulin levels in the type 2 diabetes mellitus group were
similar to the controls prior to STZ injection, whereas
insulin levels in the type 1 diabetes mellitus group were
almost undetectable (Table 1). Insulin levels for controls
and high fat diet group at the end of the study could not
be determined as hemolysis interfered with the assay.
Proteinuria and renal function
Protein to creatinine ratios are shown in Figure 3.
Creatinine clearances calculated from a 24-hour urine
collection are shown in Table 1. Animals in both the dia-
betic groups had significant proteinuria by 6 weeks com-
pared to control and high fat diet animals. There was no
increase in protein excretion noted in the high fat diet
group by the end of the study period. Creatinine clear-
ance tended to increase in all the three groups compared
to controls but was significantly elevated only in the type 2
diabetes mellitus group (Table 1). There was no signifi-
cant difference in albumin excretion rates between high
fat diet rats and controls as measured by Western blot
analysis (data not shown).
Changes in blood pressure
Systolic blood pressure in the different groups is shown
in Figure 4. Systolic blood pressure was significantly el-
evated in both diabetic groups compared to controls
by 4 weeks after induction of diabetes. Systolic blood
pressure in the high fat diet group was also signifi-
cantly elevated compared to controls by 6 weeks after
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Table 1. Chemical and histologic findings at study end (14 weeks postinduction of diabetes)
Control High fat diet Diabetes type 2 Diabetes type 1
Serum insulin ng/mL N/A N/A 0.49 ± .12a 0.07 ± .07a
Hemoglobin A1c 3.1 ± 0.12 3.3 ± 0.09 6.3 ± 0.43a 7 ± 0.36
Cholesterol 86 ± 3.14 169 ± 35a 122 ± 10a 103 ± 7
Triglycerides 60 ± 5 80 ± 18 295 ± 63a 278 ± 71a
Creatinine clearance mL/min 1.53 ± 0.21 1.87 ± 0.08 2.23 ± 0.29a 2.07 ± 0.19
Kidney weight 1.8 ± 0.1 1.43 ± 0.1 2.15 ± 0.24 1.86 ± 0.09
Kidney/body weight mg/g 3.96 ± 0.3 2.9 ± 0.29 6 ± 1.14 5.79 ± 0.32
Glom sclerosis% 2 ± 1 3.8 ± 1.3 8.3 ± 1.9a,b,c 3.2 ± 0.7
Glomerular area l2 18024 ± 2372 16636 ± 2091 17268 ± 2044 16663 ± 2350
N/A is not available. Data on insulin not available for control and high fat diet groups because hemolysis interfered with the assay.
aP < 0.05 vs. control; bP < 0.05 vs. high fat diet; cP < 0.05 vs. type 1 diabetes.
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Fig. 2. Body weight (g) at weekly intervals starting 4 weeks prior to
the end of the study period. Data are mean ± SE. High fat diet rats
were heavier than controls throughout the study period. Type 2 diabetes
mellitus (DM) rats lost less weight than type 1 diabetes mellitus rats by
the end of the study period. STZ is streptozotocin. ∗P < 0.05 vs. control;
†P < 0.05 vs. high fat diet; ‡P < 0.05 vs. type 1 diabetes mellitus.
administration of vehicle. All three groups were hyper-
tensive compared to controls by the end of the study
period.
Changes in kidney weight and kidney weight/body
weight ratio
Changes in kidney weight and kidney to body weight
ratios are shown in Table 1. There was a trend for an
increase in kidney weight in the animals with diabetes
(types 1 and 2).
Lipid profile
Plasma total cholesterol and triglyceride levels are
shown in Table 1. Total cholesterol was significantly in-
creased in high fat diet and type 2 diabetes mellitus groups
compared to controls, whereas triglycerides were ele-
vated in both diabetic groups (types 1 and 2) compared
to controls; cholesterol and triglycerides were simultane-
ously elevated only in type 2 diabetic animals.
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Fig. 3. Urinary protein excretion (mg protein/mg creatinine). Data are
mean ± SE. Type 1 diabetes mellitus (DM) rats had significantly higher
proteinuria compared to type 2 diabetes mellitus rats. The high fat diet
group did not develop proteinuria by the end of the study period. STZ
is streptozotocin. ∗P < 0.05 vs. control; †P < 0.05 vs. high fat diet; ‡P <
0.05 vs. type 1 diabetes mellitus.
Histology
The percentage of sclerosed glomeruli was signifi-
cantly higher in type 2 diabetes mellitus than in all other
groups (Table 1). There was no measurable difference in
glomerular area between groups (Table 1). Jones PAS-
stained glomeruli showed expanded mesangium in all
groups relative to control. Type 2 diabetic animals were
most affected, showing substantially more widening of
matrix than type 1 diabetes or high fat diet (Fig. 5). To
more clearly define differences among the groups, ex-
pression of fibronectin was examined and measured by
immunoperoxidase histochemistry and image analysis as
described below. The alternatively spliced fibronectin iso-
form (EIII-A) is an excellent marker not only of newly
synthesized extracellular matrix but parallels mesangial
cell activation during embryogenesis and disease [17].
Immunohistochemistry
Representative immunohistochemistry slides for cellu-
lar fibronectin and results of the morphometric analysis
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Fig. 4. Systolic blood pressure (mm Hg) measured by noninvasive tail
cuff plethysmography at 2-week interval during the study period. Data
are mean ± SE. Systolic blood pressure in type 2 diabetes mellitus (DM)
group was higher at baseline compared to high fat diet since rats were
randomized based on their body weight and not their blood pressure.
Systolic blood pressure was high in all experimental groups compared
to control at the end of the study. There was no difference in systolic
blood pressure between high fat diet, type 1 and type 2 diabetes mellitus
groups at the end of the study period. ∗P < 0.05 vs. control; †P < 0.05
vs. high fat diet; ‡P < 0.05 vs. type 1 diabetes mellitus.
are shown in Figure 6. There was light staining seen in the
control, modestly increased staining in the type 1 diabetic
group but significantly more in the type 2 diabetic group.
The high fat diet group was not evaluated because the
tissue was not suitable for immunohistochemistry. Mor-
phometric analysis of glomerular fibronectin stain area
revealed that compared to the control group there was
a significant increase in both diabetic groups. Staining of
fibronectin in type 2 diabetes was significantly increased
(fourfold) over control, whereas type 1 diabetes showed
less of an increase (threefold over control). Moreover,
the increase in fibronectin staining in type 2 diabetes was
significantly higher than in type 1 diabetes (P < 0.05).
Whole kidney levels of fibronectin on type IV collagen,
TGF-b, and CTGF
Immunoblot analyses demonstrated that fibronectin
expression was significantly increased in all three groups
compared to control (Fig. 7). The expression of type IV
collagen, TGF-b , and CTGF was significantly increased
only in high fat diet and type 2 diabetes groups (Figs. 7
and 8).
DISCUSSION
We show that rats with type 2 diabetes develop more
pronounced kidney lesions than type 1 diabetic rats de-
spite having lower urinary protein excretion rates and
lower serum glucose levels. We also show that high fat
diet alone causes significant kidney damage in the ab-
sence of proteinuria or hyperglycemia.
Data from animal experiments as well as human stud-
ies suggest a direct association between obesity, insulin
resistance, and hypertension and kidney disease. In fe-
male Fischer rats, a high fat and refined carbohydrate diet
induces insulin resistance that precedes other aspects of
the metabolic syndrome [18]. Sprague-Dawley rats fed
a high fat diet develop hypertension and morphologic
changes in the kidney suggestive of glomerulosclerosis by
10 weeks [10]. In our study, high fat diet alone was associ-
ated with hypertension and structural changes in the kid-
ney despite no evidence of proteinuria or hyperglycemia.
Although there is conclusive evidence in animal models,
as well as human studies, that lipids play an important role
in the pathogenesis of progressive renal injury, the exact
mechanism by which this occurs is still not clear. A pro-
posed mechanism for lipid-induced glomerular injury is
the increase in glomerular macrophages with release of a
number of chemical mediators and oxidized low-density
lipoprotein (LDL)–dependent oxidative stress [19, 20].
These mechanisms are analogous to the pathogenesis
of systemic atherosclerosis [21, 22]. Hyperfiltration and
glomerular hypertension secondary to efferent arterio-
lar vasoconstriction may also play an important role in
hypercholesterolemia mediated glomerular injury [23].
Our findings suggest that at least in rats, the degree of
proteinuria may be an inadequate marker of early kid-
ney disease. This suggests it is possible for patients with
metabolic syndrome (not commonly associated with ab-
normal urine protein excretion rates) to have significant
kidney damage by the time they develop diabetes based
on our observation of significant pathology in the high
fat diet group [24]. Despite the presence of significant
glomerular lesions, there was no proteinuria evident in
the animals fed a high fat diet as measured by the sensitive
Biuret protein assay. There was no microalbuminuria ev-
ident in these animals either. Hyperglycemia appears to
be a major factor in determining the presence and degree
of proteinuria. In the high fat diet group, blood glucose
and urinary protein excretion remained normal. In con-
trast, animals with type 2 diabetes had hyperglycemia and
abnormal urinary protein excretion. The degree of pro-
teinuria appears related to the degree of hyperglycemia as
animals with type 1 diabetes had higher average glucose
levels and significantly higher protein excretion rates.
However, neither proteinuria nor hyperglycemia alone
appears to correlate well with the extent of structural
damage in the kidney. Other modifying factors like hy-
pertension, hypercholesterolemia, and/or hyperinsuline-
mia seem to play an important role in the development
of kidney lesions. This is exemplified by the severity of
the histologic lesions seen in type 2 diabetic rats which
were more prominent than those seen in type 1 diabetic
animals despite lower urine protein excretion rates, lower
blood glucose levels, similar degree of hypertension, and
having received a lower dose of STZ. This suggests that
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Fig. 5. Histology [Jones periodic acid-Schiff
stain (PAS)] of representative glomeruli at
20× magnification from control, high fat
diet, type 1 and 2 diabetes mellitus (DM)
groups 14 weeks postinduction of diabetes.
Jones PAS-stained glomeruli showed ex-
panded mesangium in all experimental groups
relative to control. Type 2 diabetic animals
were most affected, showing substantially
more widening of matrix than type 1 diabets
or high fat diet.
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Fig. 6. Immunohistochemical staining of glomeruli for cellular fibronectin in frozen kidney sections (20× magnification, upper three panels).
Quantification of the% glomerular fibronectin stain area is shown in the lower panel. Fibronectin stain area was greater in both diabetes mellitus
(DM) groups compared to control but greatest in the type 2 diabetic group. Data are not available for the high fat diet group because tissue was
unsuitable for histochemistry due to technical problems (related to the processing of the tissue). ∗P < 0.05 vs. control; ‡P < 0.05 vs. type 1 diabetes
mellitus.
hyperglycemia acts synergistically with other factors like
insulin, hypertension, and hyperlipidemia to alter the
course of kidney disease.
Deregulation of growth factors appears critical in
mediating glomerular extracellular mesangial matrix
accumulation. In vitro studies have shown that high glu-
cose concentrations stimulate the expression of platelet-
derived growth factor (PDGF), CTGF, TGF-b , fibroblast
growth factor (FGF), and vascular endothelial growth
factor (VEGF) [25]. TGF-b , in particular, stimulates the
expression of fibronectin, laminin, collagen IV, and other
extracellular matrix proteins [25–27]. During the course
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Fig. 7. Immunoblot analysis of fibronectin and type IV collagen. Data are mean ± SE. Fibronectin expression in whole kidney lysates was
significantly increased in all three groups compared to controls. Type IV collagen was increased only in high fat diet (HFD) and type 2 diabetes
mellitus (DM) groups. ∗P < 0.05 vs. control.
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Fig. 8. Immunoblot analysis for transforming growth factor-b (TGF-b) and connective tissue growth factor (CTGF). Data are mean ± SE. TGF-b
and CTGF expression in whole kidney lysates was significantly increased only in high fat diet (HFD) and type 2 diabetes mellitus (DM) groups.
∗P < 0.05 vs. control.
of diabetic nephropathy, abnormal production and disor-
dered incorporation of extracellular matrix results in the
typical findings of thickening of the GBM and increased
deposition of mesangial matrix leading to glomeruloscle-
rosis and ultimately kidney failure. Different proteins
are deposited at different stages of diabetic nephropa-
thy. For example, fibronectin and collagen type IV in-
crease in the expanding mesangium throughout the whole
course of the disease. In contrast, collagen type I appears
predominantly late in the disease process. Oncofetal
2570 Danda et al: Animal model of type 2 diabetes and nephropathy
isoforms of fibronectin (ED-A and ED-B) are only
present in glomerulosclerosis but not in normal kidney
[28]. In the present study, immunoblots of whole kidney
lysates revealed significantly increased growth factor lev-
els and matrix protein expression in the high fat diet and
type 2 diabetes mellitus groups. Fibronectin was also in-
creased in the type 1 diabetes mellitus group. The reason
for the lack of change in type IV collagen and TGF-b
in type 1 diabetes mellitus observed in this study is not
clear. One possible explanation may be that whole kidney
lysates were used which could have diluted the subtle in-
creases in matrix proteins and growth factors usually seen
in glomerular extracts. For example, in a detailed analy-
sis using kidney cortex of rats with STZ-induced diabetes
(type I diabetes mellitus), Hill et al [29] demonstrated in-
creases in TGF-b isoforms and its receptors that peaked
at 3 months postinduction of diabetes and returned to
baseline level by 6 months. These results were confirmed
by Makino et al [30] who in addition to TGF-b isoforms
also investigated the time course of CTGF induction in
rats with STZ-induced diabetes. CTGF mRNA expres-
sion in glomeruli was maximal 28 days postinduction
of diabetes returning toward baseline at 3 months [30].
Therefore, in the case of CTGF, the timing of the mea-
surement could have contributed to the observed results
in type 1 rats. Nonetheless, although more sensitive stud-
ies using kidney cortex or immunohistochemistry would
likely show an increase in TGF-b in tissues from type 1
diabetic rats, the lack of change in these growth factors
and type IV collagen are in obvious contrast with the sig-
nificant increases observed in the type 2 diabetes and high
fat diet groups, the focus of our research.
Glomerular and systemic hemodynamics likely play an
important role in the development of the glomerular le-
sions we observed in the high fat diet and type 2 diabetic
rats. For example, in Dahl rats, hyperlipidemia enhances
glomerular injury through systemic and intraglomerular
hypertension. Diet-induced hypercholesterolemia wors-
ened the kidney pathology produced by hypertension in
Dahl-sensitive rats compared to rats fed a regular rat
chow low in cholesterol [31]. In contrast, in Dahl-resistant
rats (that do not develop hypertension) diet-induced hy-
percholesterolemia did not result in glomerular injury
suggesting that changes in glomerular hemodynamics
were necessary to unmask an adverse effect of hyper-
lipidemia on the kidney [31]. Similarly, in patients with
type 2 diabetes, elevated plasma cholesterol levels, blood
glucose levels, and mean blood pressure are major de-
terminants of the subsequent renal outcome [32]. Our
study also supports these findings. For a similar degree of
hypertension, kidney pathology was worse in the groups
that received a high fat diet (e.g., type 2 diabetes melli-
tus groups) compared to type 1 diabetic rats. Therefore,
hypertension alone does not seem to be the only deter-
minant of kidney pathology in these animals. The combi-
nation of hypertension and high fat diet appears to have
a synergistic effect in causing the kidney lesions in the
high fat diet group. Furthermore, the combination of hy-
perglycemia, hypertension, and dyslipidemia appears to
be significantly more detrimental to the kidney as seen in
the type 2 diabetic rats.
In obesity-prone male Sprague-Dawley rats, a moder-
ately high fat (32% of calories from fat) and high salt
diet (4% NaCl) accelerated the development of hyper-
tension and kidney sclerosis and vascular and renal ox-
idative stress compared to rats on the high fat diet but on
low salt diet instead (0.8% NaCl) [11]. In humans with
type 2 diabetes, hypertension accelerates the decline in
renal function [33]. The effect of a high salt diet in accel-
erating the hypertension and kidney lesions in this type 2
model of diabetes needs further investigation.
One of the possible drawbacks of this model is that the
potential nephrotoxic effect of STZ cannot be eliminated.
Rats still received a significant dose of STZ (35 mg/kg)
that was sufficient to induce diabetes in 40% of the rats
on a regular rat chow. The fact that type 1 diabetic rats
had less significant kidney lesions at 14 weeks despite re-
ceiving a higher dose of STZ suggests that STZ-induced
nephrotoxicity did not account for the kidney pathol-
ogy observed. The nephrotoxicity of high fat diet does
not appear to be specifically related to the particular
formulation of the diet used as other investigators have
shown similar kidney pathology with different formula-
tions of high fat diet [10, 19, 31, 34]. Also, not antici-
pating that protein excretion rates did not correlate well
with the severity of kidney pathology, rats were sacri-
ficed 14 weeks after induction of diabetes based on a
significant increase in urine protein excretion. Longer
studies are needed to determine if these animals would
develop nodular glomerulosclerosis, the hallmark of di-
abetic nephropathy in humans. For example, it was re-
cently shown in a genetic model of diabetes and kidney
disease (T2DN/Mcwi strain) that glomerular nodular le-
sions and diffuse glomerulosclerosis were apparent only
at 18 months of age but not earlier [1].
This nongenetic rat model of type 2 diabetes has sev-
eral differences and potential advantages over the con-
ventional type 1 diabetes model: (1) moderately elevated
and constant blood glucose levels without insulin admin-
istration; (2) need for insulin treatment is avoided po-
tentially rendering more homogeneous results using this
model; (3) less expensive than genetic models; (4) kid-
ney effects of hyperinsulinemia and mild hypertension
can be determined independently of hyperglycemia; and
(5) presence of prominent glomerular lesions associated
with significant increases in growth factor expression and
accumulation of extracellular matrix proteins.
The effect of dyslipidemia on the kidney in the pres-
ence or absence of hyperglycemia and proteinuria can be
determined by comparing high fat diet vs. type 2 diabetes
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groups. The effect of hyperglycemia on the kidney in the
presence or absence of dyslipidemia and hyperinsuline-
mia can be determined by comparing type 1 and type 2
diabetes groups. In this rat model of type 2 diabetes the
combination of hyperglycemia, hypertension, and dys-
lipidemia appears to be detrimental to the kidney, similar
to human type 2 diabetes and nephropathy where mul-
tiple factors appear to act synergistically to accelerate
kidney damage. Hence, we believe this is an appropriate
model to examine the effects of type 2 diabetes with as-
sociated hypertension on structural abnormalities in the
kidney.
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